Bristol-Myers Squibb Statistics, Revenue Totals, Facts & News (2022)
Last Updated on: March 27th, 2022
Here are a few of the most interesting Bristol-Myers Squibb statistics and facts I was able to dig up including revenue totals and employee counts. As always, be sure to check back in the future as I will be updating this post as new and updated stats become available.
Bristol-Myers Squibb Facts
- Bristol-Myers Squibb Website: Official Website
- Year Bristol-Myers Squibb was Founded: 1858
- Bristol-Myers Squibb Headquarters: New York City
- Bristol-Myers Squibb Founder(s): Edward Squibb (Squibb), William Bristol and John Myers (Bristol-Myers)
- Current Bristol-Myers Squibb Chief Executive: Giovanni Caforio
What is Bristol-Myers Squibb?
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our medicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience, fibrosis and others. We have built a sustainable pipeline of potential therapies, and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient at the right time to achieve the best outcome. (source)
Bristol-Myers Squibb Employee Count
Bristol-Myers Squibb number of employees:
Last updated 1/1/20
Bristol-Myers Squibb Revenue Totals
Bristol-Myers Squibb annual revenue:
- 2021: $46.385 billion
- 2020: $42.518 billion
- 2019: $26.145 billion
- 2018: $22.561 billion
- 2017: $20.776 billion
- 2016: $19.427 billion
- 2015: $16.560 billion
- 2014: $15.879 billion
- 2013: $16.385 billion
Bristol-Myers Squibb annual net earnings:
- 2021: $6.994 billion
- 2020: $8.995 billion net loss
- 2019: $3.460 billion
- 2018: $4.947 billion
- 2017: $975 million
- 2016: $4.507 billion
- 2015: $1.631 billion
- 2014: $2.029 billion
- 2013: $2.580 billion
Recent Bristol-Myers Squibb News
- Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session, 04/23/2022
- Bristol Myers Squibb Reports First Quarter Financial Results for 2022, 04/29/2022
- Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma…, 02/28/2022
- Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022, 12/17/2021
- Bristol Myers Squibb to Present at J.P. Morgan’s 40th Annual Healthcare Conference, 01/04/2022
- Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan’s 40th Annual Healthcare Conference, 01/11/2022
- Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B, 01/28/2022
Related posts:
Please note that some of these numbers are easier to find than others. A few of these Bristol-Myers Squibb stats come from their own reports, but some are based on news reports and not official company tallies. No information contained on DMR should be relied upon to make investment decisions. Basically, this is the best I can find and I don’t guarantee anything to be 100%.
Related Categories:
Related Tags: